Friedreich ataxia (FRDA) is a rare multisystem, life-limiting disease and is the most common early-onset inherited ataxia in populations of European, Arab and Indian descent. In recent years, substantial progress has been made in dissecting the pathogenesis and natural history of FRDA, and several clinical trials have been initiated. A particularly notable recent achievement was the approval of the nuclear factor erythroid 2-related factor 2 activator omaveloxolone as the first disease-specific therapy for FRDA. In light of these developments, we review milestones in FRDA translational and clinical research over the past 10 years, as well as the various therapeutic strategies currently in the pipeline. We also consider the lessons that have been learned from failed trials and other setbacks. We conclude by presenting a global roadmap for future research, as outlined by the recently established Friedreich's Ataxia Global Clinical Consortium, which covers North and South America, Europe, India, Australia and New Zealand.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41582-025-01065-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autosomal Recessive Ataxias in Northeast Brazil: A Regional Multicenter Case Series.
Cerebellum
March 2025
Division of Neurology, Department of Clinical Medicine, Universidade Federal do Ceará, Ceará, Brazil.
Unlabelled: Hereditary cerebellar ataxias are a diverse group of neurodegenerative disorders characterized by progressive cerebellar dysfunction and possible multisystemic involvement. While significant advancements have been made in understanding autosomal dominant cerebellar ataxias (ADCAs), autosomal recessive cerebellar ataxias (ARCAs) remain less extensively investigated than autosomal dominant ataxias, particularly in regions with high consanguinity. This study aimed to characterize 57 patients with ARCAs in Ceará, northeast Brazil.
View Article and Find Full Text PDFCorrigendum to "Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1/AMPK, KEAP1, and GSK3β in the impairment of the NRF2 response" [Redox Biol. 76 (2024) 103339].
Redox Biol
March 2025
Department de Ciències Mèdiques Bàsiques, IRBLleida, Universitat de Lleida, Catalonia, Spain. Electronic address:
Continuous Optimization of a Hierarchical Bayesian Network for Friedreich's Ataxia Severity Classification.
Annu Int Conf IEEE Eng Med Biol Soc
July 2024
Machine learning algorithms for rare disorders, such as Friedreich's Ataxia (FRDA), often suffer from a lack of data. Therefore, the ability for continuous optimization of an objective assessment model would be very useful as a clinical decision support system. In this study, we propose a Bayesian Network(BN) system for FRDA severity estimation that incorporates a Bayesian Statistical updating system to continuously improve the predictive ability while providing an easily interpretable graphical model.
View Article and Find Full Text PDFSpinocerebellar Ataxia Progression Measured with the Patient-Reported Outcome Measure of Ataxia.
Mov Disord
March 2025
Ataxia Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Background: The Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia) has been validated cross-sectionally but not longitudinally.
Objective: We aimed to validate PROM-Ataxia as a measure of patient experience of disease over time, examine overall and domain-specific progression, and test convergent validity with other clinical outcome assessments (COAs).
Methods: We derived PROM-Ataxia data from 176 patients with spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, or 10 in the Clinical Research Consortium for the Study of Cerebellar Ataxia at baseline and 1 year.
A global perspective on research advances and future challenges in Friedreich ataxia.
Nat Rev Neurol
March 2025
Center for Rare Movement Disorders Innsbruck, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Friedreich ataxia (FRDA) is a rare multisystem, life-limiting disease and is the most common early-onset inherited ataxia in populations of European, Arab and Indian descent. In recent years, substantial progress has been made in dissecting the pathogenesis and natural history of FRDA, and several clinical trials have been initiated. A particularly notable recent achievement was the approval of the nuclear factor erythroid 2-related factor 2 activator omaveloxolone as the first disease-specific therapy for FRDA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!